Cargando…

Is there a moderate range of impact of financialization on corporate R&D?

How to promote corporate research and development is a particularly important issue under the background of the economy being diverted out of the real economy. By selecting samples of 1221 Chinese A-share non-financial listed companies from 2010 to 2019, this paper examines the impact of financializ...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhenghui, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244881/
https://www.ncbi.nlm.nih.gov/pubmed/34191824
http://dx.doi.org/10.1371/journal.pone.0253380
_version_ 1783716013182812160
author Li, Zhenghui
Wang, Yan
author_facet Li, Zhenghui
Wang, Yan
author_sort Li, Zhenghui
collection PubMed
description How to promote corporate research and development is a particularly important issue under the background of the economy being diverted out of the real economy. By selecting samples of 1221 Chinese A-share non-financial listed companies from 2010 to 2019, this paper examines the impact of financialization on research and development through the panel threshold regression model. Then, the moderate range of the impact of financialization on corporate research and development is measured, as well as their heterogeneity is also analyzed. The research shows the following results: first, there is a dynamic relationship and moderate range between financialization and corporate research and development. Financialization has a positive effect on corporate research and development when the level of financialization exceeds 0.4748. Secondly, from further heterogeneous research, financialization has a threshold effect on research and development among enterprises with a high level of research and development. In addition, there is a promoting effect on corporate research and development only when their financialization level exceeds 0.0097 in enterprises with a high level of research and development. Therefore, in order to promote corporate research and development, financialization of non-financial enterprises should make adjustment and regulation according to the action and direction of moderate range.
format Online
Article
Text
id pubmed-8244881
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-82448812021-07-12 Is there a moderate range of impact of financialization on corporate R&D? Li, Zhenghui Wang, Yan PLoS One Research Article How to promote corporate research and development is a particularly important issue under the background of the economy being diverted out of the real economy. By selecting samples of 1221 Chinese A-share non-financial listed companies from 2010 to 2019, this paper examines the impact of financialization on research and development through the panel threshold regression model. Then, the moderate range of the impact of financialization on corporate research and development is measured, as well as their heterogeneity is also analyzed. The research shows the following results: first, there is a dynamic relationship and moderate range between financialization and corporate research and development. Financialization has a positive effect on corporate research and development when the level of financialization exceeds 0.4748. Secondly, from further heterogeneous research, financialization has a threshold effect on research and development among enterprises with a high level of research and development. In addition, there is a promoting effect on corporate research and development only when their financialization level exceeds 0.0097 in enterprises with a high level of research and development. Therefore, in order to promote corporate research and development, financialization of non-financial enterprises should make adjustment and regulation according to the action and direction of moderate range. Public Library of Science 2021-06-30 /pmc/articles/PMC8244881/ /pubmed/34191824 http://dx.doi.org/10.1371/journal.pone.0253380 Text en © 2021 Li, Wang https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Li, Zhenghui
Wang, Yan
Is there a moderate range of impact of financialization on corporate R&D?
title Is there a moderate range of impact of financialization on corporate R&D?
title_full Is there a moderate range of impact of financialization on corporate R&D?
title_fullStr Is there a moderate range of impact of financialization on corporate R&D?
title_full_unstemmed Is there a moderate range of impact of financialization on corporate R&D?
title_short Is there a moderate range of impact of financialization on corporate R&D?
title_sort is there a moderate range of impact of financialization on corporate r&d?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244881/
https://www.ncbi.nlm.nih.gov/pubmed/34191824
http://dx.doi.org/10.1371/journal.pone.0253380
work_keys_str_mv AT lizhenghui isthereamoderaterangeofimpactoffinancializationoncorporaterd
AT wangyan isthereamoderaterangeofimpactoffinancializationoncorporaterd